Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.

被引：0
|
作者：
Bachelot, T.
Bajard, A.
Ray-Coquard, I
Coeffic, D.
Dramais, D.
Ferri-Dessens, R.-M.
Guastalla, J.-P.
Perol, D.
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Hosp, Annecy, France
[3] Inst Daniel Hollard, Grenoble, France
[4] Ctr Hosp, Valence, France
[5] Roche France, Paris, France
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：625S / 625S
页数：1
相关论文
共 50 条
  • [41] High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer
    Milla-Santos, A
    Rallo, L
    Solano, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (02): : 138 - 142
  • [42] Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients:: preliminary results.
    Bayo, J
    Salvador, J
    Lomas, M
    Ruiz, M
    Baena, J
    Vicente, D
    Bernabé, R
    Pineda, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 91S - 91S
  • [43] A COMPARISON OF FIRST-LINE TREATMENT WITH GEMCITABINE PLUS DOCETAXEL VERSUS GEMCITABINE PLUS VINORELBINE IN WOMEN WITH METASTATIC BREAST CANCER
    Bensalem, A.
    Bouzid, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [44] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    S. H. Waters
    A. Gillibrand
    H. Berry
    S. Kumar
    G. Velikova
    D. J. Dodwell
    Timothy J. Perren
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 407 - 412
  • [45] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    Waters, S. H.
    Gillibrand, A.
    Berry, H.
    Kumar, S.
    Velikova, G.
    Dodwell, D. J.
    Perren, Timothy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 407 - 412
  • [46] Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.
    Chan, S
    Romieu, G
    Huober, J
    Delozier, T
    Tubiana-Hulin, M
    Lluch, A
    Schneeweiss, A
    Llombart, A
    Carrasco, E
    Fumoleau, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 24S - 24S
  • [47] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [48] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06): : 1171 - 1177
  • [49] Docetaxel and mitoxantrone, versus docetaxel mitoxantrone and letrozole as first-line therapy in advanced breast cancer: A randomized study.
    Gennatas, C
    Mouratidou, D
    Tsavaris, N
    Michalaki, V
    Psychogios, J
    Poulakaki, N
    Andreadis, C
    Diamantopoulos, N
    Gennatas, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 58S - 58S
  • [50] Docetaxel followed by epirubicin plus docetaxel as primary systemic therapy for large operable breast cancer
    Frutuoso, Cristina
    Henriques, Isabel
    Pazos, Isabel
    Abraul, Elsa
    Pego, Antonio
    Belo, Joana
    Campos, Ondina
    Gervasio, Helena
    De Oliveira, Carlos F.
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 66
12345